A circulating inhibitor of platelet aggregation in Bartter's syndrome.
A circulating inhibitor of platelet aggregation in Bartter's syndrome.
复制标题
巴特综合征中血小板聚集的循环抑制剂。
作者：
S. O'Reagan;G. Rivard;J. Mongeau;P. Robitaille
对5例Bartter综合征患者的血小板进行了聚集研究。肾上腺素未能诱导聚集在所有五名患者。5 '-二磷酸腺苷（ADP）产生单一可逆的聚集相，并且对胶原蛋白的敏感性降低。对利托那韦的反应正常。将患者血浆加入正常富血小板血浆中，对ADP诱导的血小板聚集有剂量相关的抑制作用。当患者接受阿司匹林治疗时，这种抑制作用减弱或消失。两名不再接受阿司匹林治疗的患者的洗涤血小板显示出对正常贫血小板血浆中肾上腺素的正常反应。在阿司匹林治疗期间，1例患者的出血时间从23分钟缩短至12分钟。这些研究表明，血小板聚集的循环抑制剂，可能是前列腺素的来源，是目前在与巴特综合征患者的血浆。
Aggregation studies were performed on platelets from five patients with Bartter's syndrome. Epinephrine failed to induce aggregation in all five patients. Adenosine 5'-diphosphate (ADP) produced a single reversible phase of aggregation, and there was depressed sensitivity to collagen. Response to ristocetin was normal. There was a dose-related inhibition of ADP-induced platelet aggregation when plasma from the patients was addeded to normal platelet-rich plasma. This inhibition was diminished or absent when patients were receiving aspirin. Washed platelets from two patients who were no longer undergoing aspirin therapy, showed a normal response to epinephrine in normal platelet-poor plasma. Bleeding time was reduced from 23 minutes to 12 minutes in one patient while on aspirin therapy. These studies suggest that a circulating inhibitor of platelet aggregation, probably of prostaglandin origin, is present in the plasma of patients with Bartter's syndrome.